Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.35 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.35 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.35 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.35 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.35 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.35 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.35 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.35 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.35 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.35 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6786990 | 0.88 | ELANE (0.36) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6786987 | 0.88 | ELANE (0.36) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6787073 | 0.85 | ALDH1A1 (0.32) | ROCK2 | |
| SCHEMBL6793511 | 0.84 | CDK2 (0.33) | CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6793245 | 0.84 | CCNA2 (0.37) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6794272 | 0.83 | CCNA2 (0.37) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6792409 | 0.82 | TEAD2 (0.38) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6791848 | 0.82 | BRAF (0.37) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL6789049 | 0.82 | CDK2 (0.37) | BRAFEIF2AK3CCNA2CDK2CCNA1 | |
| SCHEMBL6790309 | 0.82 | CCNA2 (0.43) | BRAFEIF2AK3CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | BRAF 316/4885EIF2AK3 500/4885CCNA2 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.